Finanzen von Jin Medical International Ltd (ZJYL)ZJYLJin Medical International Ltd

Jin Medical International Ltd (ZJYL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Wheelchair, accounting for 72.9% of total sales, equivalent to $7.69M. Another important revenue stream is Wheelchair components and others. Understanding this composition is critical for investors evaluating how ZJYL navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Jin Medical International Ltd maintains a gross margin of 25.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.60%, while the net margin is -0.90%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ZJYL converts its operational activities into shareholder value.

In the context of the broader market, ZJYL competes directly with industry leaders such as OBIO and MOBI. With a market capitalization of $340.91M, it holds a significant position in the sector. When comparing efficiency, ZJYL's gross margin of 25.63% stands against OBIO's 71.59% and MOBI's 83.21%. Such benchmarking helps identify whether Jin Medical International Ltd is trading at a premium or discount relative to its financial performance.

The stock has a very high P/E ratio of 147.30 and a price-to-sales ratio of 7.76, indicating potential overvaluation. The forward P/E is currently at 0, reflecting uncertainty in future earnings. The company has also experienced a significant decline in stock price, down 54.47% year-to-date and 67.17% over the past year.